1
Sigal Irving S, Huff Joel R, Darke Paul L, Vacca Joseph P, Young Steven D, Desolms S Jane, Thompson Wayne J, Lyle Terry A, Graham Samuel L, Ghosh Arun K: Hiv protease inhibitors useful for the treatment of aids.. Merck & Co, October 18, 1989: EP0337714-A2 (242 worldwide citation)

Compounds of the form A-G-B-B-J wherein A is an amine protecting group commonly employed in peptide synthesis, G a dipeptide isostere, B an amino acid or analog thereof, and J a small terminal group are described. These compounds are useful in the inhibition of HIV protease, the prevention or treatm ...


2
Desolms S Jane, Huff Joel R, Vacca Joseph P, Sigal Irving S, Darke Paul L, Young Steven D: Hiv protease inhibitors useful for the treatment of aids.. Merck & Co, February 28, 1990: EP0356223-A2 (214 worldwide citation)

Compounds of the form, A-G-B-B-J wherein A is an amine protecting group not useful or commonly employed in peptide synthesis, G a dipeptide isostere, B an amino acid or analog thereof, and J a small terminal group are described. These compounds are useful in the inhibition of HIV protease, the preve ...


3
Sigal Irving S, Huff Joel R, Darke Paul L: Renin inhibitors useful for the treatment of aids by inhibition of hiv protease.. Merck & Co, March 7, 1990: EP0357332-A2 (30 worldwide citation)

Certain renin inhibitors are useful in the inhibition of HIV protease, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immun ...


4
Darke Paul L, Jacobs Amanda R, Kuo Lawrence C: Hepatitis c virus replication inhibitors. Merck & Co, Darke Paul L, Jacobs Amanda R, Kuo Lawrence C, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, March 8, 2001: WO/2001/016379 (1 worldwide citation)

The present application identifies the NS4A binding site present on NS2/3 as a target site for inhibiting NS2/3 protease activity. Methods inhibiting NS2/3 activity by targeting the identified target site are described along with examples of compounds useful in such methods and guidance for obtainin ...


5
Darke Paul L, Hall Dawn L, Kuo Lawrence C: Purified herpes simplex virus protease and methods of purification. Merck & Co, June 11, 1997: EP0777727-A1

A method of purifying proteases from the Herpes Simplex Virus 1 and 2 is taught. A precursor protease is cloned in a host cell and then separated from the cell culture using cation exchange chromatography. The resulting protease is subjected to autoprocessing conditions and an autolytic cleavage occ ...


6

7
Darke Paul L, Hall Dawn L, Kuo Lawrence C: Purified herpes simplex virus protease and methods of purification. Merck & Co, Darke Paul L, Hall Dawn L, Kuo Lawrence C, sMERCK 126 East Lincoln Avenue Rahway NJ 07065, February 8, 1996: WO/1996/003498

A method of purifying proteases from the Herpes Simplex Virus 1 and 2 is taught. A precursor protease is cloned in a host cell and then separated from the cell culture using cation exchange chromatography. The resulting protease is subjected to autoprocessing conditions and an autolytic cleavage occ ...


8
Darke Paul L, Jacobs Amanda R, Kuo Lawrence C: Hepatitis c virus replication inhibitors. Merck & Co, June 19, 2002: EP1214454-A1

The present application identifies the NS4A binding site present on NS2/3 as a target site for inhibiting NS2/3 protease activity. Methods inhibiting NS2/3 activity by targeting the identified target site are described along with examples of compounds useful in such methods and guidance for obtainin ...